Dermatologic Manifestations of Hypereosinophilic Syndrome Clinical Presentation

  • Author: Noah S Scheinfeld, MD, JD, FAAD; Chief Editor: Dirk M Elston, MD   more...
 
Updated: Aug 2, 2011
 

History

Hypereosinophilic syndrome is a multisystem disease, and the presenting complaint can vary depending on the organ involved. It is possible for hypereosinophilic syndrome to only involve the skin.[13] The presentation can be acute (eg, stroke), as when cardiac and neurologic systems are involved, or, more commonly, hypereosinophilic syndrome has an insidious onset. In an NIH series[9] , common symptoms included fatigue (26%), cough (24%), breathlessness (16%), muscle pains or angioedema (14%), and fever (12%). Sweating and pruritus are common. Mucocutaneous manifestations occur in 25-50% of patients. Eosinophilia was incidentally detected in 12% of patients with hypereosinophilic syndrome. Patients with hypereosinophilic syndrome can have low-grade fevers. Some patients with hypereosinophilic syndrome experience alcohol intolerance with abdominal pain, flushing, nausea, weakness, or diarrhea. Rare associations with lupus[14] and leptomeningeal syndrome[15] for hypereosinophilic syndromehave been reported.

  • Mucocutaneous manifestations of hypereosinophilic syndrome[16, 17]
    • Common manifestations of hypereosinophilic syndrome
      • Pruritus
      • Urticaria
      • Dermatographism
      • Angioedema
      • Erythematous papules, plaques, and nodules
      • Nonspecific rashes
    • Uncommon manifestations of hypereosinophilic syndrome
      • Aquagenic pruritus[18]
      • Splinter hemorrhages
      • Palpable purpura
      • Livedoid discoloration
      • Wells syndrome[19]
      • Livedoid discoloration
      • Erythroderma
      • Vesicular disease
      • Eosinophilic vasculitis
      • Acral necrosis[20]
      • Petechiae
      • Erythema annulare centrifugum
      • Mucosal ulceration and erythema
      • Bullous pemphigoid (responded to imatinib)[21]
  • Cardiac symptoms of hypereosinophilic syndrome[22, 23, 24, 25, 26]
    • The heart is commonly involved, and thromboembolic complications resulting from cardiac involvement can lead to multisystem disease.
    • Heart damage evolves through 3 stages: (1) an acute necrotic stage (with a mean disease duration of 5.5 wk), (2) a thrombotic stage (10-mo mean duration of eosinophilia), and (3) a fibrotic stage (after approximately 2-y duration of disease).
    • In summary, hypereosinophilic syndrome can result in endomyocardial fibrosis, valvular disease and lesions, mural thrombus formation, cardiomegaly due to infiltration of the myocardium with eosinophils, and pericardial effusion.
    • Symptoms are most common during the thrombotic and fibrotic phases and include chest pain, dyspnea, and orthopnea.
  • Neurologic symptoms of hypereosinophilic syndrome[27, 28]
    • Thromboembolic complications are usually from the heart and present as strokes or transient ischemic attacks (TIAs).[29]
    • Primary CNS dysfunction usually presents with symptoms of encephalopathy, such as behavior changes, confusion, blurry vision, memory loss, ataxia, and upper motor neuron signs.
    • Peripheral neuropathies present as symmetric or asymmetric sensory changes, pure motor deficits, mixed sensory and motor defects, or paresthesias. The cause is poorly understood. Peripheral neuropathies cause 50% of all neurologic complications.
  • Pulmonary symptoms of hypereosinophilic syndrome
    • Pulmonary symptoms may result from CHF, pulmonary emboli from the right side of the heart, or infiltration of the lungs by eosinophils.
    • The most common symptom is a chronic, nonproductive cough. Dyspnea may occur due to CHF or pleural effusions (which are sometimes primarily caused by hypereosinophilic syndrome). Bronchospasm asthmatic symptoms can occur.
  • Hematologic symptoms of hypereosinophilic syndrome[30, 31]
    • Nonspecific symptoms, such as fatigue due to anemia or easy bruising due to thrombocytopenia, can occur. Eosinophils can cause vasculitis; therefore, vasculitis in different organs, including the skin, can be associated with hypereosinophilic syndrome. Some cases evolve into eosinophilic leukemia or other forms of leukemia.
    • Thrombotic episodes often occur and present with neurologic complications. The thrombotic events may occur secondary to heart dysfunction, or they may be caused by hypercoagulability. The mechanism of hypercoagulability remains to be fully defined.
  • GI symptoms of hypereosinophilic syndrome
    • GI involvement can occur secondary to embolic disease from the heart or from eosinophil infiltration of the GI tract, the liver, or the spleen.
    • Splenomegaly presents with left upper quadrant pain and occurs in about 40% of patients.
    • Diarrhea occurs in 20% of patients.
    • Abdominal pain, vomiting, and nausea can occur. The stomach may become dilated.
    • Liver and gall bladder dysfunction and ascites can also result. A report has noted hypereosinophilic syndrome and sclerosing cholangitis. In such cases, the symptoms and blood parameters of liver dysfunction can be associated with eosinophilia and high serum IgE levels. During corticosteroid therapy, these parameters improve, and morphologic improvements of the bile ducts can also usually be observed. The pathogenesis of sclerosing cholangitis may be explained, in part, by the concept of hypereosinophilic syndrome or allergic reaction.
    • Ulcers, hepatitis, gastritis, colitis, pancreatitis, Budd-Chiari syndrome, and cholangitis can occur.
    • Watanabe et al[32] reported a 64-year-old man with hypereosinophilic syndrome. This patient had from dysphagia, swelling of the oral mucosa and the posterior cervical muscles, abdominal pain, and diarrhea. This elderly man had an abnormal number of eosinophils in his blood. CT scanning revealed thickening of the posterior wall of the pharynx, esophagus, and GI tract. A lower lip tissue specimen demonstrated a moderate infiltration of eosinophils.
  • Rheumatologic symptoms of hypereosinophilic syndrome: Arthralgia, arthritis, Raynaud phenomenon, and Wells syndrome have been reported with hypereosinophilic syndrome.
  • Ocular symptoms of hypereosinophilic syndrome
    • Visual symptoms, especially blurring, can occur.
    • Adie syndrome (pupillotonia), keratoconjunctivitis, and episcleritis can occur.
    • Retinal and blood vessel abnormalities can occur, more often as a result of microthrombi than arteritis.
  • Constitutional symptoms of hypereosinophilic syndrome
    • Many patients experience fever and night sweats.
    • Anorexia and weight loss are uncommon presenting symptoms; these symptoms are often related to an underlying cardiac disease.
  • Other symptoms of hypereosinophilic syndrome: Oligospermia has been reported in a patient receiving imatinib therapy for the hypereosinophilic syndrome. Hypereosinophilic syndrome with heart involvement occurred in a pregnant woman with multiple sclerosis.[33]
Next

Physical

The signs and symptoms are dependent on the organ system involved.

  • Mucocutaneous signs of hypereosinophilic syndrome
    • Urticarial wheals (see image below) and angioedema are common.Urticarial and erythematous rash. Urticarial and erythematous rash.
    • Dermatographism occurs in as many as 75% of patients.
    • Erythematous, pruritic papules and plaques are the other major dermatologic manifestation.
    • Blistering lesions and necrotic ulcers secondary to dermal microthrombi have been reported.
    • Petechiae, generalized erythroderma, erythema annulare centrifugum, and Raynaud phenomenon are other cutaneous manifestations, as seen in the image below. Petechiae on an erythematous base. Petechiae on an erythematous base.
    • Splinter hemorrhages can result from cardiac thromboemboli.
    • Ulcers can occur on virtually any mucosal surface.
  • Cardiac signs of hypereosinophilic syndrome
    • Signs of heart disease vary depending on the stage of involvement, and they become more prominent in the latter stages of the disease.
    • Splinter hemorrhages, arrhythmias, murmurs (particularly mitral and tricuspid regurgitation), restrictive cardiomyopathy, cardiomegaly, as well as other CHF manifestations all occur and have a worse prognosis. The symptoms of hypereosinophilic syndrome can resemble restrictive cardiac disease.
  • Neurologic signs of hypereosinophilic syndrome
    • Acute neurologic deficits are usually the result of thromboembolic disease.
    • Primary CNS involvement manifests as changes in mental status, ataxia, increased deep muscle tone, increased deep tendon reflexes, and a positive Babinski sign. Seizures can occur but are less common.
    • When peripheral nerves are involved, patients exhibit sensory and/or motor deficits. Radiculopathies, muscle atrophy from denervation, and mononeuritis multiplex have been reported. Generalized weakness has been noted but is not a diagnostic sign of hypereosinophilic syndrome.
  • Pulmonary signs of hypereosinophilic syndrome
    • Pleural effusions are common as a result of CHF.
    • Diffuse or focal crackles may be appreciated as a result of pulmonary infiltration by eosinophils or by ensuing pulmonary fibrosis.
    • Pleuritic chest pain and hypoxia can be caused by pulmonary emboli originating from the right side of the heart.
  • GI signs of hypereosinophilic syndrome
    • Because hypereosinophilic syndrome can affect every abdominal organ, complaints of abdominal pain need to be immediately evaluated.
    • Bowel necrosis, with the classic "pain out of proportion to examination," due to thromboembolic disease is life threatening.
    • Splenomegaly is common.
  • Rheumatologic signs of hypereosinophilic syndrome
    • Joint effusions can occur.
    • The characteristic color changes of Raynaud phenomenon may be observed.
  • Ocular signs of hypereosinophilic syndrome: Occasional visual blurring may occur.
Previous
Next

Causes

Hypereosinophilic syndrome is a clonal proliferation of eosinophils. By definition, hypereosinophilic syndrome is an idiopathic condition.

  • Some have speculated that hypereosinophilic syndrome is not primarily a disease of eosinophils but rather a disease of T cells that secrete cytokines that result in such clonal proliferations. Such clonal eosinophils are activated and have more eosinophilic mediators than normal eosinophils.
  • Some cases of hypereosinophilic syndrome turn into leukemia, and, as such, chromosomal abnormalities are at the root of some cases of hypereosinophilic syndrome. A study from the NIH[9] found chromosomal abnormalities in 8 of 33 patients examined. Such abnormalities can include the Philadelphia chromosome.
Previous
 
 
Contributor Information and Disclosures
Author

Noah S Scheinfeld, MD, JD, FAAD  Assistant Clinical Professor, Department of Dermatology, Columbia University College of Physicians and Surgeons; Consulting Staff, Department of Dermatology, St Luke's Roosevelt Hospital Center, Beth Israel Medical Center, and New York Eye and Ear Infirmary; Private Practice

Noah S Scheinfeld, MD, JD, FAAD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Optigenex Consulting fee Independent contractor

Coauthor(s)

Felix Urman, MD  Staff Physician, Department of Dermatology, St Luke's Roosevelt Hospital Center

Disclosure: Nothing to disclose.

Specialty Editor Board

Takeji Nishikawa, MD  Emeritus Professor, Department of Dermatology, Keio University School of Medicine; Director, Samoncho Dermatology Clinic; Managing Director, The Waksman Foundation of Japan Inc

Disclosure: Nothing to disclose.

David F Butler, MD  Professor of Dermatology, Texas A&M University College of Medicine; Chair, Department of Dermatology, Director, Dermatology Residency Training Program, Scott and White Clinic, Northside Clinic

David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Association of Military Dermatologists, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Jeffrey P Callen, MD  Professor of Medicine (Dermatology), Chief, Division of Dermatology, University of Louisville School of Medicine

Jeffrey P Callen, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and American College of Rheumatology

Disclosure: Amgen Honoraria Consulting; Abbott Honoraria Consulting; Electrical Optical Sciences Consulting fee Consulting; Celgene Honoraria Safety Monitoring Committee; GSK - Glaxo Smith Kline Consulting fee Consulting; TenXBioPharma Consulting fee Safety Monitoring Committee

Catherine M Quirk, MD  Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania

Catherine M Quirk, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD  Director, Ackerman Academy of Dermatopathology, New York

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

References
  1. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore). Jan 1975;54(1):1-27. [Medline].

  2. Roufosse FE, Goldman M, Cogan E. Hypereosinophilic syndromes. Orphanet J Rare Dis. Sep 11 2007;2:37. [Medline].

  3. Gonzalez Delgado P, de la Sen Fernandez ML, Soriano Gomis V, Perez Crespo M, Munoz Ruiz C, Hernandez Niveiro E. Cyclical hypereosinophilia with skin manifestations and a clonal T cell population. J Investig Allergol Clin Immunol. 2008;18(5):401-3. [Medline].

  4. Simon HU, Plötz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med. Oct 7 1999;341(15):1112-20. [Medline].

  5. Chung KF, Hew M, Score J, et al. Cough and hypereosinophilia due to FIP1L1-PDGFRA fusion gene with tyrosine kinase activity. Eur Respir J. Jan 2006;27(1):230-2. [Medline].

  6. Martinaud C, Souraud JB, Cournac JM, Pons S, Ménard G, de Jaureguiberry JP, et al. [Synchronous detection of T-cell clonality and FIP1L1-PDGFRA fusion gene in a hypereosinophilic syndrome.]. Rev Med Interne. Jul 2010;[Medline].

  7. Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood. Nov 15 2004;104(10):3038-45. [Medline].

  8. McPherson T, Cowen EW, McBurney E, Klion AD. Platelet-derived growth factor receptor-alpha-associated hypereosinophilic syndrome and lymphomatoid papulosis. Br J Dermatol. Oct 2006;155(4):824-6. [Medline].

  9. Fauci AS, Harley JB, Roberts WC, Ferrans VJ, Gralnick HR, Bjornson BH. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med. Jul 1982;97(1):78-92. [Medline].

  10. Farruggia P, D'Angelo P, Acquaviva A, et al. Hypereosinophilic syndrome in childhood: clinical and molecular features of two cases. Pediatr Hematol Oncol. Apr-May 2009;26(3):129-35. [Medline].

  11. Alfaham MA, Ferguson SD, Sihra B, Davies J. The idiopathic hypereosinophilic syndrome. Arch Dis Child. Jun 1987;62(6):601-13. [Medline].

  12. Kim HY, Kim YM, Kim SH, Kim HJ. Encephalitis in idiopathic hypereosinophilic syndrome in childhood. Pediatr Radiol. Jun 2010;[Medline].

  13. Sundaramurthi VL, Prabhavathy D, Somasundaram SV, Wahab AJ. Hypereosinophilic syndrome: cutaneous involvement as the sole manifestation. Indian J Dermatol. Jan 2011;56(1):107-9. [Medline]. [Full Text].

  14. Habibagahi Z, Ali Nazarinia M, Aaflaki E, Ali Ostovan M, Hadi Bagheri M. Systemic lupus erythematosus and hyper-eosinophilic syndrome: an unusual association. West Indian Med J. Jan 2009;58(1):69-71. [Medline].

  15. Kanamori M, Suzuki H, Sato I, Ohyama K, Tezuka F, Katakura R. A case of idiopathic hypereosinophilic syndrome with leptomeningeal dissemination and intraventricular mass lesion: an autopsy report. Clin Neuropathol. May-Jun 2009;28(3):197-202. [Medline].

  16. Leiferman KM, Gleich GJ, Peters MS. Dermatologic manifestations of the hypereosinophilic syndromes. Immunol Allergy Clin North Am. Aug 2007;27(3):415-41. [Medline].

  17. Ionescu MA, Murata H, Janin A. Oral mucosa lesions in hypereosinophilic syndrome--an update. Oral Dis. Mar 2008;2:115-22. [Medline].

  18. Newton JA, Singh AK, Greaves MW, Spry CJ. Aquagenic pruritus associated with the idiopathic hypereosinophilic syndrome. Br J Dermatol. Jan 1990;122(1):103-6. [Medline].

  19. Bogenrieder T, Griese DP, Schiffner R, et al. Wells' syndrome associated with idiopathic hypereosinophilic syndrome. Br J Dermatol. Dec 1997;137(6):978-82. [Medline].

  20. Takekawa M, Imai K, Adachi M, et al. Hypereosinophilic syndrome accompanied with necrosis of finger tips. Intern Med. Nov 1992;31(11):1262-6. [Medline].

  21. Hofmann SC, Technau K, Muller AM, Lubbert M, Bruckner-Tuderman L. Bullous pemphigoid associated with hypereosinophilic syndrome: simultaneous response to imatinib. J Am Acad Dermatol. May 2007;56(5 Suppl):S68-72. [Medline].

  22. Brockington IF, Olsen EG. Loffler's endocarditis and Davies endomyocardial fibrosis. Am Heart J. 1973;85:308.

  23. Davies J, Spry CJ, Sapsford R, et al. Cardiovascular features of 11 patients with eosinophilic endomyocardial disease. Q J Med. Winter 1983;52(205):23-39. [Medline].

  24. Rauch AE, Amyot KM, Dunn HG, Ng B, Wilner G. Hypereosinophilic syndrome and myocardial infarction in a 15-year-old. Pediatr Pathol Lab Med. May-Jun 1997;17(3):469-86. [Medline].

  25. Tan SA, Duggal A. Pericardial involvement as a rare manifestation of hypereosinophilic syndrome. South Med J. Jul 2009;102(7):751-3. [Medline].

  26. Fernandez AB, Ahmed S, Duncan B, Firshein S, Kluger J. Cardiac tamponade: a rare complication of idiopathic hypereosinophilic syndrome. J Cardiovasc Med (Hagerstown). Feb 2009;10(2):188-91. [Medline].

  27. Moore PM, Harley JB, Fauci AS. Neurologic dysfunction in the idiopathic hypereosinophilic syndrome. Ann Intern Med. Jan 1985;102(1):109-14. [Medline].

  28. Grigoryan M, Geisler SD, St Louis EK, Baumbach GL, Davis PH. Cerebral arteriolar thromboembolism in idiopathic hypereosinophilic syndrome. Arch Neurol. Apr 2009;66(4):528-31. [Medline].

  29. Chang WL, Lin HJ, Cheng HH. Hypereosinophilic syndrome with recurrent strokes: a case report. Acta Neurol Taiwan. Sep 2008;17(3):184-8. [Medline].

  30. Flaum MA, Schooley RT, Fauci AS, Gralnick HR. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. I. Hematologic manifestations. Blood. Nov 1981;58(5):1012-20. [Medline].

  31. Numagami Y, Tomita T, Murakami K, Masaki I, Kubo K, Michiharu N. Sinus thrombosis in idiopathic hypereosinophilic syndrome causing fatal cerebral haemorrhage. J Clin Neurosci. May 2008;15(5):585-7. [Medline].

  32. Watanabe M, Matsui N, Hamada S, et al. A rare case of idiopathic hypereosinophilic syndrome involving the oral cavity associated with the esophagus and gastrointestinal tract. Intern Med. Apr 2004;43(4):336-9. [Medline].

  33. Darki A, Kodali PP, McPheters JP, Virk H, Patel MR, Jacobs W. Hypereosinophilic syndrome with cardiac involvement in a pregnant patient with multiple sclerosis. Tex Heart Inst J. 2011;38(2):163-5. [Medline]. [Full Text].

  34. Kahn JE, Bletry O, Guillevin L. Hypereosinophilic syndromes. Best Pract Res Clin Rheumatol. Oct 2008;22(5):863-82. [Medline].

  35. Zittoun J, Farcet JP, Marquet J, Sultan C, Zittoun R. Cobalamin (vitamin B12) and B12 binding proteins in hypereosinophilic syndromes and secondary eosinophilia. Blood. Apr 1984;63(4):779-83. [Medline].

  36. Rothenberg ME. Molecular diagnostics and treatment of patients with the hypereosinophilic syndrome. Clin Adv Hematol Oncol. Jan 2009;7(1):43-4. [Medline].

  37. Adams JC, Dal-Bianco JP, Kumar G, Callahan MJ. Hypereosinophilic syndrome with characteristic left ventricular thrombus demonstrated bycontrast echocardiography. Neth Heart J. Apr 2009;4:169-70. [Medline].

  38. Scheinfeld N. A comprehensive review of imatinib mesylate (Gleevec) for dermatological diseases. J Drugs Dermatol. Feb 2006;5(2):117-22. [Medline].

  39. Coutre S, Gotlib J. Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. Semin Cancer Biol. Aug 2004;14(4):307-15. [Medline].

  40. Kobayashi M, Kubota T, Uemura Y, Taguchi H. A case of hypereosinophilic syndrome presenting with chronic cough successfully treated with imatinib. Respirology. Mar 2009;14(2):302-4. [Medline].

  41. Gleich GJ, Leiferman KM. The hypereosinophilic syndromes: current concepts and treatments. Br J Haematol. May 2009;145(3):271-85. [Medline].

  42. Wagner LA, Speckart S, Cutter B, Gleich GJ. Treatment of FIP1L1/PDGFRA-negative hypereosinophilic syndrome with alemtuzumab, an anti-CD52 antibody. J Allergy Clin Immunol. Jun 2009;123(6):1407-8. [Medline].

  43. Verstovsek S, Tefferi A, Kantarjian H, et al. Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res. Jan 1 2009;15(1):368-73. [Medline].

  44. Quintas-Cardama A, Cortes J. Therapeutic options for patients with clonal and idiopathic hypereosinophia. Expert Opin Investig Drugs. Jul 2008;17(7):1039-50. [Medline].

  45. Wechsler ME. Combating the eosinophil with anti-interleukin-5 therapy. N Engl J Med. Mar 20 2008;358(12):1293-4. [Medline].

  46. Marshall GM, White L. Effective therapy for a severe case of the idiopathic hypereosinophilic syndrome. Am J Pediatr Hematol Oncol. Summer 1989;11(2):178-83. [Medline].

  47. Parrillo JE, Fauci AS, Wolff SM. Therapy of the hypereosinophilic syndrome. Ann Intern Med. Aug 1978;89(2):167-72. [Medline].

  48. Razaq W, Beautyman E. Successful Treatment of Refractory Idiopathic Hypereosinophilic Syndrome With Etoposide. Am J Ther. Jan 8 2009;[Medline].

  49. Walsh GM. Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions. Curr Opin Mol Ther. Jun 2009;11(3):329-36. [Medline].

  50. Donald CE, Kahn MJ. Successful treatment of hypereosinophilic syndrome with cyclosporine. Am J Med Sci. Jan 2009;337(1):65-6. [Medline].

  51. Taverna JA, Lerner A, Goldberg L, Werth S, Demierre MF. Infliximab as a therapy for idiopathic hypereosinophilic syndrome. Arch Dermatol. Sep 2007;143(9):1110-2. [Medline].

Previous
Next
 
Urticarial and erythematous rash.
Petechiae on an erythematous base.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.